Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand
-
US Food and Drug Administration accepts New Drug Application for daprodustat
US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat
-
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
Myelofibrosis is a fatal cancer of the bone marrow impacting the normal production of blood cells.
-
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
According to UNAIDS, approximately 1.7 million children globally were living with HIV in 2020.
-
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment.
-
GSK to demonstrate its commitment to improving outcomes for patients with gynaecologic cancer at the 2022 SGO Annual Meeting
The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022
-
GSK announces appointments to Designate Haleon Board
GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the appointment of six directors to the designate Board of Haleon.
-
European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat
The EMA has validated the MAA for daprodustat, for the treatment of patients with anaemia of chronic kidney disease.
-
GSK introduces Haleon to investors
Global leader in consumer health set to be a newly independent company
-
GSK provides further update on phase III RSV maternal vaccine candidate programme
Further to the voluntary pause shared on February 18, the Company has decided to stop enrolment and vaccination in trials
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
A vaccine manufactured in plants and developed in Canada
-
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials
-
GSK announces independent Consumer Healthcare company is to be called Haleon
Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands.
-
GSK provides update on phase III RSV maternal vaccine candidate programme
GSK gives update on RSV maternal vaccine candidate
-
China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis
First and only biologic approved in China for both systemic lupus erythematosus and lupus nephritis
-
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER; Total EPS 87.6p -24% AER, -13% CER and Adjusted EPS of 113.2p -2% AER, +9% CER
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER.
-
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
ViiV Healthcare to present new long-term findings at CROI 2022
-
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement
Gilead will make an upfront payment of $1.25 billion to ViiV Healthcare in the first quarter of 2022
-
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.
-
Tony Wood appointed Chief Scientific Officer designate, GSK
Tony Wood appointed Chief Scientific Officer designate, GSK
